Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Homology Medicines stock | 10.01

Own Homology Medicines stock in just a few minutes.


Fact checked

Homology Medicines, Inc is a biotechnology business based in the US. Homology Medicines shares (FIXX) are listed on the NASDAQ and all prices are listed in US Dollars. Homology Medicines employs 197 staff and has a trailing 12-month revenue of around USD$2.2 million.

How to buy shares in Homology Medicines

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Homology Medicines. Find the stock by name or ticker symbol: FIXX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Homology Medicines reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$10.01, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Homology Medicines, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Homology Medicines. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Homology Medicines's share price?

Since the stock market crash in March caused by coronavirus, Homology Medicines's share price has had significant negative movement.

Its last market close was USD$10.01, which is 43.37% down on its pre-crash value of USD$17.675 and 20.98% down on the lowest point reached during the March crash when the shares fell as low as USD$12.11.

If you had bought USD$1,000 worth of Homology Medicines shares at the start of February 2020, those shares would have been worth USD$905.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$597.30.

Homology Medicines share price

Use our graph to track the performance of FIXX stocks over time.

Homology Medicines shares at a glance

Information last updated 2020-10-19.
Latest market close USD$10.01
52-week range USD$9.65 - USD$22.5
50-day moving average USD$10.7901
200-day moving average USD$13.4051
Wall St. target price USD$29.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.179

Buy Homology Medicines shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Homology Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Homology Medicines price performance over time

Historical closes compared with the close of $10.01 from 2020-11-16

1 week (2020-11-20) 1.52%
1 month (2020-10-27) -10.47%
3 months (2020-08-27) -5.92%
6 months (2020-05-27) -32.36%
1 year (2019-11-27) -35.63%
2 years (2018-11-27) -50.74%
3 years (2017-11-23) N/A
5 years (2015-11-23) N/A

Homology Medicines financials

Revenue TTM USD$2.2 million
Gross profit TTM USD$-87,732,000
Return on assets TTM -26.91%
Return on equity TTM -51.92%
Profit margin 0%
Book value $4.307
Market capitalisation USD$495.1 million

TTM: trailing 12 months

Shorting Homology Medicines shares

There are currently 4.4 million Homology Medicines shares held short by investors – that's known as Homology Medicines's "short interest". This figure is 19.7% down from 5.5 million last month.

There are a few different ways that this level of interest in shorting Homology Medicines shares can be evaluated.

Homology Medicines's "short interest ratio" (SIR)

Homology Medicines's "short interest ratio" (SIR) is the quantity of Homology Medicines shares currently shorted divided by the average quantity of Homology Medicines shares traded daily (recently around 462294.46764092). Homology Medicines's SIR currently stands at 9.58. In other words for every 100,000 Homology Medicines shares traded daily on the market, roughly 9580 shares are currently held short.

However Homology Medicines's short interest can also be evaluated against the total number of Homology Medicines shares, or, against the total number of tradable Homology Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Homology Medicines's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Homology Medicines shares in existence, roughly 100 shares are currently held short) or 0.1315% of the tradable shares (for every 100,000 tradable Homology Medicines shares, roughly 132 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Homology Medicines.

Find out more about how you can short Homology Medicines stock.

Homology Medicines share dividends

We're not expecting Homology Medicines to pay a dividend over the next 12 months.

Homology Medicines share price volatility

Over the last 12 months, Homology Medicines's shares have ranged in value from as little as $9.65 up to $22.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Homology Medicines's is -0.2644. This would suggest that Homology Medicines's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Homology Medicines has bucked the trend.

Homology Medicines overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site